The first AI-discovered drug to reach late-stage trials is being tested in China, where regulators moved faster than the FDA.

The Shanghai startup's mega-round signals a fresh wave of capital chasing AI drug discovery in China, with investors betting on domestic rivals to Anthropic and Isomorphic Labs.